In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus

Virology

Volumn 259, Issue 2, 1999, Pages 416-427

  Raabe, Michelle L ^c   Issel, Charles J ^b   Montelaro, Ronald C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACULOVIRUS RECOMBINANT ENVELOPE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE SUBUNIT VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; DISEASE SEVERITY; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; VACCINATION; VIRUS REPLICATION;

ANIMALIA; EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; RNA VIRUSES; UNIDENTIFIED BACULOVIRUS;

EID: 0033526769     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1999.9772     Document Type: Article

References (65)

1. Bolognesi, D.1989. Do antibodies enhance the infection of cells by HIV?Nature340, 431-432.
2. Burke D. Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk? Perspect. Biol. Med. 35:1992;511-530.
3. Burke D. S. Human trials of experimental HIV vaccines. AIDS. 9:1995;S171-S180.
4. Clements J. E., Zink M. C. Molecular biology and pathogenesis of animal lentivirus infections. Clin. Microbiol. Rev. 9:1996;100-117.
5. Clements J. E., Zink M. C., Narayan O. Lentivirus infection of macrophages. Immunol. Ser. 60:1994;538-600.
6. Cohen J. The HIV vaccine paradox. Science. 264:1994;1072-1074.
7. Coligan J. E., Kruisbeek A. M., Margulies D. H., Shevach E. M., Strober W. Coico R. Current Protocols in Immunology. 1994;Wiley, New York.
8. Connor R. I., Dinces N. B., Howell A. L., Romet-Lemonne J.-L., Pasquali J.-L., Fanger M. W. Fc receptors for IgG (FcγRs) on human monocytes and macrophages are not infectivity receptors for human immunodeficiency virus type 1 (HIV-1): Studies using bispecific antibodies to target HIV-1 to various myeloid cell surface molecules, including the FcγR. Proc. Natl. Acad. Sci. USA. 88:1991;9593-9597.
9. Crawford T. B., Wardrop K. J., Tornquist S. J., Reilich E., Meyers K. M., McGuire T. C. A primary production deficit in thrombocytopenia of equine infectious anemia. J. Virol. 70:1996;7842-7850.
10. Flynn J. N., Cannon C. A., Neil J. C., Jarrett O. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not offer protection. J. Virol. 71:1997;7586-7592.
11. Fust G., Toth F., Kiss J., Ujhelyi E., Nagy I., Banhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. AIDS. 8:1994;603-609.
12. Gardner M., Rosenthal A., Jennings M., Yee J., Antipa L., Robinson J. E. Jr. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Human Retroviruses. 11:1995;843-854.
13. Halsted S. Immune enhancement of viral infection. Prog. Allergy. 31:1982;301-364.
14. Hammond S. A., Cook S. J., Lichtenstein D. L., Issel C. J., Montelaro R. C. Maturation of the cellular and humoral immune response to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71:1997;3840-3852.
15. Haubrich R., Takeda A., Koff W., Smith G., Ennis F. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine. J. Infect. Dis. 165:1992;545-548.
16. Homsy J., Meyer M., Levy J. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J. Virol. 64:1990;1437-1440.
17. Homsy J., Meyer M., Tateno M., Clarkson S., Levy J. A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science. 244:1989;1357-1360.
18. Homsy J., Tateno M., Levy J. Antibody-dependent enhancement of HIV infection. Lancet. i:1988;1285-1286.
19. Hosie M., Osborne R., Reid G., Neil J., Oswald J. Enhancement after feline immunodeficiency virus vaccination. Vet. Immunol. Immunopathol. 35:1992;191-197.
20. Issel, C, Cook, R. F, Cook, S, Raabe, M. L, and, Montelaro, R. C. Manuscript in preparation.
21. Issel C. J., Horohov D. W., Lea D. F., Adams W. V. Jr., Hagius S. D., McManus J. M., Allison A. C., Montelaro R. C. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. Virology. 66:1992;3398-3408.
22. Jolly P. E., Huso D., Hart G., Narayan O. Modulation of lentivirus replication by antibodies. Non-neutralizing antibodies to caprine arthritis-encephalitis virus enhance early stages of infection in macrophages, but do not cause increased production of virions. J. Gen. Virol. 70:1989a;2221-2226.
23. Jolly P. E., Huso D. L., Sheffer D., Narayan O. Modulation of lentivirus replication by antibodies: Fc portion of immunoglobulin molecule is essential for enhancement of binding, internalization and neutralization of visna virus in macrophages. J. Virol. 63:1989b;1811-1813.
24. Kennedy-Stoskopf S., Narayan O. Neutralizing antibodies to visna lentivirus: Mechanism of action and possible role in virus persistence. J. Virol. 59:1986;37-44.
25. Kliks S., Nisalak A., Brandt W., Wahl L., Burde D. Antibody-dependent enhancement of Dengue virus growth in human monocytes as a risk factor for Dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:1989;444-451.
26. Lombardi S., Garzelli C., Pistello M., Massi C., Matteucci D., Baldinotti F., Cammarota G., Prato L., Bandecchi P., Tozzini F., Bendinelli M. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J. Virol. 68:1994;8374-8379.
27. Lu S., Arthos J., Montefiori D. C., Yasutomi Y., Manson K., Mustafa F., Johnson E., Santoro J. C., Wissink J., Mullins J. I., Haynes J. R., Letvin N. L., Wyand M., Robinson H. L. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:1996;3978-3991.
28. Mascola J. R., Mathieson B. J., Zack P. M., Walker M. C., Halstead S. B., Burke D. S. Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res. Human Retroviruses. 9:1993;1175-1184.
29. McGuire T., Adams D., Johnson G., Klevjer-Anderson P., Barbee P., Gorham J. Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats. J. Vet. Res. 47:1986;537-540.
30. Messaoudi K. E., Englert Y., Steens M., Thiry L., Tieghem N. V. HIV-1 infectivity enhanced by a cathepsin-like activity in vaginal secretions. Arch. Int. Physiol. Biochim. Biophys. 102:1994;B34.
31. Montefiori D., Murphey-Corb M., Desrosiers R., Daniel M. Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus. J. Virol. 64:1990a;5223-5225.
32. Montefiori D., Pantaleo G., Fink L., Zhou J. T., Zhou J. Y., Bilska M., Miralles G., Fauci A. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173:1996a;60-67.
33. Montefiori D., Reimann K., Letvin N., Zhou J., Hu S.-L. Studies of complement-activating antibodies in the SIV/macaque model of acute primary infection and vaccine protection. AIDS Res. Human Retroviruses. 11:1995;963-970.
34. Montefiori D., Robinson W., Hirsch V., Modliszewski A., Mitchell W., Johnson P. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J. Virol. 64:1990b;113-119.
35. Montefiori D. C., Baba T. W., Li A., Bilska M., Ruprecht R. M. Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J. Immunol. 157:1996b;5528-5535.
36. Montefiori D. C., Lefkowitz L. B., Keller R. E., Holmberg V., Sandstrom E., Phair J. P. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1 infected individuals. AIDS. 5:1991;513-517.
37. Morens D. M. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clinical Infectious Diseases. 19:1994;500-512.
38. Nara P. L., Merges M. S. M., Conley S., Hogervorst E., Goudsmit J., Henderson L., Arthur L., Dunlop N. Human plasma proteins and HIV-1: A missing link in our understanding of the pathobiology. AIDS Res. Hum. Retroviruses. 10:1994;S71.
39. Narayan O., Clements J. E. Biology and pathogenesis of lentiviruses. J. Gen. Virol. 70:1989;1617-1639.
40. Nathanson N., Martin J. R., Georgsson G., Palsson P. A., Lutley R. E., Petursson G. The effect of post-infection immunization on the severity of experimental visna. J. Comp. Pathol. 91:1981;185-189.
41. O'Brian W. A., Grovit-Ferbas K., Namazi A., Ovcak-Derzic S., Wang H.-J., Park J., Yeramian C., Mao S.-H., Zack J. A. Human immunodeficiency virus-type 1 replication can be increased in the peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;1082-1089.
42. Olsen C., Corapi W., Ngichabe C., Baines J., Scott F. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J. Virol. 66:1992;956-965.
43. Perno C.-F., Baseler M. W., Broder S., Yarchoan R. Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies. J. Exp. Med. 171:1990;1043-1056.
44. Porterfield J. S. Antibody-dependent enhancement of viral infectivity. J. Adv. Virus Res. 31:1986;335-353.
45. Raabe M. L., Issel C. J., Cook S. J., Cook R. F., Woodson B., Montelaro R. C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology. 245:1998a;151-162.
46. Raabe M. L., Issel C. J., Montelaro R. C. Equine monocyte-derived macrophage cultures and their applications for infectivity and neutralization studies of equine infectious anemia virus. J. Virol. Methods. 71:1998b;87-104.
47. Richardson W., Moraillon A., Baud S., Cuisinier A.-M., Sonigo P., Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J. Virol. 71:1997;9640-9649.
48. Robinson W., Montefiori D., Mitchell W. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet. 1:1988;790-794.
49. Robinson W., Montefiori D., Mitchell W., Prince A., Alter H., Dreesman G., Eichberg J. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees. Proc. Natl. Acad. Sci. USA. 86:1989;4710-4714.
50. Robinson W. E., Gorny M. K., Xu J.-Y., Mitchell W. M., Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 65:1991;4169-4176.
51. Robinson W. E., Kawamura T., Lake D., Masuho Y., Mitchell W. M., Hersh E. M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J. Virol. 64:1990a;5301-5305.
52. Robinson W. E., Montefiori D. C., Mitchell W. M. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology. 175:1990b;600-604.
53. Rwambo P. M., Issel C. J., Hussain K. A., Montelaro R. C. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch. Virol. 111:1990;275-280.
54. Schlienger K., Montefiori D., Mancini M., Riviere Y., Tiollais P., Michel M. Vaccine-induced neutralizing antibodies directed in part to simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J. Virol. 68:1994;6578-6580.
55. Shadduck P. P., Weinberg J. B., Haney A. F., Bartlett J. A., Langlois A. L., Bolognesi D. P., Matthews T. J. Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. J. Virol. 65:1991;4309-4316.
56. Siebelink K., Tijhaar E., Huisman R., Huisman W., De Ronde A., Darby I., Francis M., Rimmelzwaan G., Osterhaus A. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J. Virol. 69:1995;3704-3711.
57. Spear G. T. Interaction of non-antibody factors with HIV in plasma. AIDS. 7:1993;1149-1157.
58. Stanley S. K., Ostrowski M. A., Justement J. S., Gantt K., Hedayati S., Mannix M., Roche K., Schwartzentruber D. J., Fox C. H., Fauci A. S. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334:1996;1222-1230.
59. Takeda A., Ennis F. A. FcR-mediated enhancement of HIV-1 infection by antibody. AIDS Res. Hum. Retroviruses. 6:1990;999-1004.
60. Takeda A., Sweet R. W., Ennis F. A. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and FcγR. J. Virol. 64:1990;5605-5610.
61. Takeda A., Tuazon C. U., Ennis F. A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science. 242:1988;580-583.
62. Tornquist S. J., Oaks J. L., Crawford T. B. Elevation of cytokines associated with the thrombocytopenia of equine infectious anemia. J. Gen. Virol. 78:1997;2541-2548.
63. Toth F., Szabo B., Ujhelyi E., Paloczi K., Horvath A., Fust G., Kiss J., Banhegyi D., Hollan S. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS. 5:1991;263-268.
64. Wang S., Rushlow K., Issel C., Cook R., Cook S., Raabe M., Chong Y.-H., Costa L., Montelaro R. C. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology. 199:1994;247-251.
65. Wu S.-C., Spouge J., Conley S., Tsai W.-P., Merges M., Nara P. Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages. J. Virol. 69:1995;6054-6062.